Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood-Clotting showdown: which device best guides bleeding care in High-Risk patients?

NCT ID NCT06635564

Knowledge-focused Sponsor: Medical University of Vienna Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study compares three devices that measure how well blood clots — ClotPro, ROTEM, and TEG — in patients undergoing liver surgery, neurosurgery, or cesarean section. The goal is to see how closely the results from these devices agree with each other. The findings may help doctors choose the best tool for personalized bleeding management, but the test results will not be used to guide treatment during this study.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help identify which device provides the most accurate and reliable blood-clotting information, potentially improving bleeding management in high-risk surgeries and childbirth.
What could go wrong
This is an observational comparison study, not a treatment trial. The results may not directly change patient care, and the devices may show similar performance, limiting the impact.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

240 people

The number who actually took part.

Started

Jul 2024

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will be comprised of three groups: 1. Patients with liver disease undergoing elective liver surgery defined as one of the following invasive procedures a) liver resection (anatomic or non-anatomic segmental resection, right or left hepatectomy, right or left extended hepatectomy) or b) orthotopic liver transplantation. 2. Pregnant women undergoing elective cesarean section. 3. Patients undergoing elective intracranial neurosurgery

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Vulnerable patient cohorts * Patients undergoing elective liver surgery defined as one of the following invasive procedures: * Liver resection (anatomic or non-anatomic segmental resection, right or left hepatectomy, right or left extended hepatectomy), * Orthotopic liver transplantation, * Pregnant women undergoing an elective caesarean section, and * Patients undergoing an elective intracranial neurosurgery. 2. Written informed consent Exclusion Criteria: none

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bleeding disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemorrhagic disease intracerebral hemorrhage Intracranial Hemorrhages liver disorder Postpartum Hemorrhage vascular hemostatic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bleeding disorder Intracranial hemorrhages Liver transplant Postpartum hemorrhage Thrombelastography

Contacts and locations

Locations

  • Medical University of Vienna

    Vienna, Austria, 1090, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.